Medicare AdvantageCoverageLow impact
MA08.089d, Cerliponase alfa (Brineura®)
Independence Blue Cross·Neurology, Pediatrics·Pharmacy
Effective date
Dec 10, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.089d for Cerliponase alfa (Brineura®) has been reissued and updated. This pharmacy policy affects coverage and billing requirements for this rare enzyme replacement therapy used to treat neuronal ceroid lipofuscinosis type 2 (CLN2 disease).
Action Required
By December 10, 2025: Billing team should review the updated Cerliponase alfa (Brineura®) policy at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing procedures for Medicare Advantage patients receiving this specialty medication.